Acetylcysteine augmentation with Rispridone in treatment of Autism in childre
Phase 2
- Conditions
- Pervasive developmental disorders.Childhood autism
- Registration Number
- IRCT201106103930N6
- Lead Sponsor
- Vice chancellor for research, Shiraz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Inclusion Criteria: DSM-IV diagnosis of autism spectrum disorders; both gender, aged 3 to 16 years.
Exclusion Criteria
primary diagnosis of a psychotic disorder; active substance abuse or dependence; unstable medical condition; prior exposure to N-Acetylcysteine; evidence of active liver disease; seizure disorder; unstable hypertension or cardiac disease; unstable asthma; and kidney disease as determined by the investigator; Weight < 15 kg.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method